<!doctype html>
<html lang="en">
<head>
<meta charset="utf-8">
<title>Annotated example</title>
<style>
body {
  font-family: ui-sans-serif, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji", "Segoe UI Emoji";
  margin: 24px;
  color: #111827;
  background: #ffffff;
}
.container {
  max-width: 920px;
  margin: 0 auto;
}
.header {
  margin-bottom: 20px;
}
.subtle {
  color: #6b7280;
  font-size: 14px;
}
.message {
  white-space: pre-wrap;
  line-height: 1.6;
  font-size: 16px;
  background: #fafafa;
  border: 1px solid #e5e7eb;
  border-radius: 8px;
  padding: 16px;
}
.legend {
  display: flex;
  gap: 12px;
  flex-wrap: wrap;
  margin: 12px 0 20px 0;
}
.legend-item {
  display: inline-flex;
  align-items: center;
  gap: 8px;
  font-size: 14px;
}
.badge {
  display: inline-block;
  border-radius: 6px;
  padding: 4px 8px;
  border: 1px solid #d1d5db;
  background: #f3f4f6;
  color: #374151;
  font-weight: 600;
}
.ann {
  border-radius: 4px;
  padding: 0 2px;
  border-width: 1px;
  border-style: solid;
}
.sidebar {
  margin-top: 24px;
  border-top: 1px solid #e5e7eb;
  padding-top: 12px;
}
.sidebar h3 {
  margin: 8px 0;
  font-size: 16px;
}
.sidebar .ann-item {
  margin-bottom: 10px;
  font-size: 14px;
}
blockquote {
  margin: 0 0 12px 0;
  border-left: 3px solid #d1d5db;
  padding-left: 12px;
  color: #4b5563;
}
a {
  color: #2563eb;
  text-decoration: none;
}
a:hover {
  text-decoration: underline;
}
.footer {
  margin-top: 24px;
  font-size: 12px;
  color: #6b7280;
}
</style>
</head>
<body>
<div class="container">
  <div class="header">
    <h2>Annotated Assistant Response</h2>
    <div class="legend"><span class="legend-item"><span class="badge" style="background:#e6ffed;border-color:#34d058;color:#22863a">Supported</span></span><span class="legend-item"><span class="badge" style="background:#ffeef0;border-color:#f85149;color:#b31d28">Not Supported</span></span><span class="legend-item"><span class="badge" style="background:#fff5e5;border-color:#f2a654;color:#9a6700">Insufficient Information</span></span></div>
    <div class="subtle"><strong>pubmedqa_id:</strong> 27456836</div>
<div class="subtle"><strong>original_answer:</strong> yes</div>
<div class="subtle"><strong>context:</strong> To explore whether electrochemiluminescence (ECL) assays can help improve prediction of time to type 1 diabetes in the TrialNet autoantibody-positive population. TrialNet subjects who were positive for one or more autoantibodies (microinsulin autoantibody, GAD65 autoantibody [GADA], IA-2A, and ZnT8A) with available ECL-insulin autoantibody (IAA) and ECL-GADA data at their initial visit were analyzed; after a median follow-up of 24 months, 177 of these 1,287 subjects developed diabetes. Univariate analyses showed that autoantibodies by radioimmunoassays (RIAs), ECL-IAA, ECL-GADA, age, sex, number of positive autoantibodies, presence of HLA DR3/4-DQ8 genotype, HbA1c, and oral glucose tolerance test (OGTT) measurements were all significantly associated with progression to diabetes. Subjects who were ECL positive had a risk of progression to diabetes within 6 years of 58% compared with 5% for the ECL-negative subjects (P&lt;0.0001). Multivariate Cox proportional hazards models were compared, </div>
<div class="subtle"><strong>source:</strong> pubmedqa_meditron</div>
<div class="subtle"><strong>user_prompt:</strong> Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?</div>
  </div>
  <div class="message">yes
Explanation: The addition of <span class="ann" title="Supported: ECL-IAA (electrochemiluminescence insulin autoantibody) is a real assay mentioned throughout the study by Fouts et al. 2016 in Diabetes Care." style="background:#e6ffed;border-color:#34d058;color:#22863a;">ECL-IAA</span> and <span class="ann" title="Supported: ECL-GADA (electrochemiluminescence glutamic acid decarboxylase autoantibody) is a real assay mentioned throughout the study by Fouts et al. 2016 in Diabetes Care." style="background:#e6ffed;border-color:#34d058;color:#22863a;">ECL-GADA</span> to the current <span class="ann" title="Supported: TrialNet (Type 1 Diabetes TrialNet) is a real international consortium that conducts studies on type 1 diabetes prevention and is the subject of the study in question." style="background:#e6ffed;border-color:#34d058;color:#22863a;">TrialNet</span> autoantibody panel <span class="ann" title="Supported: The study conclusions state &#x27;ECL assays improved the ability to predict time to diabetes in these antibody-positive relatives at risk for developing diabetes.&#x27;" style="background:#e6ffed;border-color:#34d058;color:#22863a;">improved prediction of time to diabetes</span>. <span class="ann" title="Not Supported: The actual study conclusion states &#x27;These findings might be helpful in both the monitoring of subjects at risk for diabetes and the design of prevention trials in the future.&#x27; There is no mention of needing confirmation in other populations in the conclusions section." style="background:#ffeef0;border-color:#f85149;color:#b31d28;">These results should be confirmed in other populations</span>.</div>
  <div class="sidebar"><h3>Placed annotations</h3><div class="ann-item"><span class="badge" style="background:#e6ffed;border-color:#34d058;color:#22863a">Supported</span> <strong>ECL-IAA</strong> (idx 33) — ECL-IAA (electrochemiluminescence insulin autoantibody) is a real assay mentioned throughout the study by Fouts et al. 2016 in Diabetes Care.</div><div class="ann-item"><span class="badge" style="background:#e6ffed;border-color:#34d058;color:#22863a">Supported</span> <strong>ECL-GADA</strong> (idx 45) — ECL-GADA (electrochemiluminescence glutamic acid decarboxylase autoantibody) is a real assay mentioned throughout the study by Fouts et al. 2016 in Diabetes Care.</div><div class="ann-item"><span class="badge" style="background:#e6ffed;border-color:#34d058;color:#22863a">Supported</span> <strong>TrialNet</strong> (idx 69) — TrialNet (Type 1 Diabetes TrialNet) is a real international consortium that conducts studies on type 1 diabetes prevention and is the subject of the study in question.</div><div class="ann-item"><span class="badge" style="background:#e6ffed;border-color:#34d058;color:#22863a">Supported</span> <strong>improved prediction of time to diabetes</strong> (idx 97) — The study conclusions state &#x27;ECL assays improved the ability to predict time to diabetes in these antibody-positive relatives at risk for developing diabetes.&#x27;</div><div class="ann-item"><span class="badge" style="background:#ffeef0;border-color:#f85149;color:#b31d28">Not Supported</span> <strong>These results should be confirmed in other populations</strong> (idx 138) — The actual study conclusion states &#x27;These findings might be helpful in both the monitoring of subjects at risk for diabetes and the design of prevention trials in the future.&#x27; There is no mention of needing confirmation in other populations in the conclusions section.</div></div>
  
  <div class="footer">Generated by annotate_from_spans.py</div>
</div>
</body>
</html>